Evidence map›Paper›PMID 26036700›Full record

ArticleMacromolecular bioscience2015

Curcumin Targeted, Polymalic Acid-Based MRI Contrast Agent for the Detection of Aβ Plaques in Alzheimer's Disease.

Rameshwar Patil, Pallavi R Gangalum, Shawn Wagner, Jose Portilla-Arias, Hui Ding, Arthur Rekechenetskiy, Bindu Konda, Satoshi Inoue, Keith L Black, Julia Y Ljubimova and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Macromolecular bioscience, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 42 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. A Review of the Role of Curcumin in Metal Induced Toxicity.Antioxidants (Basel, Switzerland) · 2023
    Review
  9. Review
  10. Article
  11. Polymalic acid for translational nanomedicine.Journal of nanobiotechnology · 2022
    Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Rameshwar PatilNanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, California, 90048, USA.
Pallavi R GangalumNanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, California, 90048, USA.
Shawn WagnerBiomedical Imaging Research Institute, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California, 90048, USA.
Jose Portilla-AriasNanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, California, 90048, USA.
Hui DingNanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, California, 90048, USA.
Arthur RekechenetskiyNanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, California, 90048, USA.
Bindu KondaNanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, California, 90048, USA.
Satoshi InoueNanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, California, 90048, USA.
Keith L BlackNanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, California, 90048, USA.
Julia Y LjubimovaNanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, California, 90048, USA.
Eggehard HollerNanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, California, 90048, USA. hollere@cshs.org.
Cedars-Sinai Medical Center · US

Funding

Differential MRI imaging for brain tumor metastases diagnosis and treatment monitoringR01CA188743 · NCI · CEDARS-SINAI MEDICAL CENTER · PI LJUBIMOVA, JULIA Y · 2015 to 2019
$2.5M
NCI NIH HHS R01 CA188743
6 · The paper itself

Abstract

Currently, there is no gadolinium-based contrast agent available for conventional magnetic resonance imaging (MRI) detection of amyloidal beta (Aβ) plaques in Alzheimer's disease (AD). Its timely finding would be vital for patient survival and quality of life. Curcumin (CUR), a common Indian spice effectively binds to Aβ plaques which is a hallmark of AD. To address this binding, we have designed a novel nanoimaging agent (NIA) based on nature-derived poly(β-l-malic acid) (PMLA) containing covalently attached gadolinium-DOTA(Gd-DOTA) and nature-derived CUR. The all-in-one agent recognizes and selectively binds to Aβ plaques and is detected by MRI. It efficiently detected Aβ plaques in human and mouse samples by an ex vivo staining. The method can be useful in clinic for safe and noninvasive diagnosis of AD.

Indexed as

Magnetic Resonance ImagingAlzheimer DiseaseAnimalsBrainContrast MediaCurcuminHeterocyclic CompoundsHumansMalatesMiceOrganometallic CompoundsPlaque, AmyloidPolymersContrast MediaCurcumingadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetateHeterocyclic CompoundsMalatesOrganometallic Compoundspoly(malic acid)PolymersAlzheimer diseasecurcumin; MRInanoimaging agentpolymalic acid

Identifiers

PMID26036700
PMCPMC4794283
OpenAlexW1588526262

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.